Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indacaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.92 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.92 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.92 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.92 |
| ▸ | HTR2A | P28223 | 1/20 | 0.92 |
| ▸ | HTR2C | P28335 | 1/20 | 0.92 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.92 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.92 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.92 |
| ▸ | DRD3 | P35462 | 1/20 | 0.92 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.92 |
| ▸ | SRSF6 | Q13247 | 1/20 | 0.92 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.92 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indacaterol SCHEMBL29379269 | 1.00 | ADRB2 (0.92) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4009719 | 1.00 | ADRB2 (0.92) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4015376 | 0.99 | ADRB2 (0.91) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4015381 | 0.99 | ADRB2 (0.91) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL159597 | 0.96 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL48098 | 0.96 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4186345 | 0.96 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29798949 | 0.96 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29350045 | 0.96 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29367297 | 0.96 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236478-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2021-08-05 | — | — | US | claimed |
| US-20190282561-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2019-09-19 | — | — | US | claimed |
| US-20180071276-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | claimed |
| US-20160101097-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | claimed |
| US-20130237564-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2013-09-12 | — | — | US | claimed |
| US-8436017-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | claimed |
| EP-2332915-B1 | Beta2-adrenoceptor agonists | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | claimed |
| US-20120316142-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | LOHSE OLIVIER (FR) | 2012-12-13 | — | — | US | claimed |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD (GB) | 2012-11-29 | — | — | US | claimed |
| EP-2044025-B1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | claimed |
| US-8198450-B2 | Quinolinone derivatives and their pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-12 | — | — | US | claimed |
| US-20090325912-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | claimed |
| EP-2044025-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 2009-04-08 | — | — | EP | claimed |
| WO-2008000839-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | claimed |
| WO-2020202130-A2 | IMPROVED PROCESS FOR THE PREPARATION OF INDACATEROL MALEATE | NEULAND LABORATORIES LIMITED (IN) | 2020-10-08 | — | — | WO | disclosed |
| EP-3022202-B1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-10183025-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2019-01-22 | — | — | US | disclosed |
| US-20090325912-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-2044025-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008000839-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071276-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885SLC6A2 1034/4885 |
| US-20160101097-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885SLC6A2 1021/4885 |
| US-20210236478-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885SLC6A2 1020/4885 |
| US-20120316142-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885SLC6A2 301/4885 |
| US-20190282561-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 6/4885SLC6A2 987/4885 |
| US-20090325912-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885SLC6A2 301/4885 |
| US-20130237564-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885SLC6A2 1034/4885 |
| US-10183025-B2 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | ADRB2 3743/4885ADRB1 3413/4885SLC6A2 3157/4885 |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885SLC6A2 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.